S'abonner

Clinical significance of lncRNA XIST expression in cholangiocarcinoma and its effect on cell migration and invasion - 28/06/24

Doi : 10.1016/j.clinre.2024.102398 
Chenxi Li a, #, Yifei Dong b, #, Yichuan Zhang c, , Caihong Wu d, e, f,
a Department of General Surgery, Wenling Hospital of Traditional Chinese Medicine, Wenling 317500, China 
b Department of Laboratory, The Eighth Hospital of Wuhan, Wuhan 430010, China 
c Minimally Invasive Endoscopy Center, Digestive Disease Center, The Affiliated Hospital of Panzhihua University, Panzhihua 617000, China 
d Department of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha 421001, China 
e Anesthesia Medical Research Center of Central South University, Changsha 421001, China 
f Department of Clinical Nursing, The Second Xiangya Hospital of Central South University, Changsha 421001, China 

⁎⁎Corresponding author at: Department of Anesthesiology, The Second Xiangya Hospital of Central South University; Anesthesia Medical Research Center of Central South University; Department of Clinical Nursing, The Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha 421001, China.Department of AnesthesiologyThe Second Xiangya Hospital of Central South UniversityAnesthesia Medical Research Center of Central South UniversityDepartment of Clinical NursingThe Second Xiangya Hospital of Central South UniversityNo. 139, Renmin Middle Road, Furong DistrictChangsha421001ChinaCorresponding author at: Minimally Invasive Endoscopy Center, Digestive Disease Center, The Affiliated Hospital of Panzhihua University, 27 Taoyuan Street, East District, Panzhihua 617000, China.Minimally Invasive Endoscopy CenterDigestive Disease CenterThe Affiliated Hospital of Panzhihua University27 Taoyuan Street, East DistrictPanzhihua617000China

Hightlights

XIST may serve as a prognostic biomarker for cholangiocarcinoma.
Overexpression of XIST inhibited tumor progression by targeting miR-126–3p.
XIST has a carcinogenic role in cholangiocarcinoma.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Cholangiocarcinoma is a malignant tumor that occurs in the bile duct system, and the prognosis of patients is poor. Currently, research suggests that long non-coding RNAs (lncRNAs) in the treatment and prevention of cholangiocarcinoma. This study primarily focuses on the regulation and potential mechanism of the lncRNA XIST (XIST) in cholangiocarcinoma.

Methods

The levels of XIST and miR-126–3p in cholangiocarcinoma tissues and cells were detected using real-time quantitative polymerase chain reaction (RT-qPCR). Cell transfection status, including migration and invasion, was examined via the Transwell method. The relationship between XIST and miR-126–3p was observed by dual-luciferase gene reporter assay and verified by rescue assays. Additionally, the prognostic significance of XIST in cholangiocarcinoma was determined using Kaplan-Meier and multivariate Cox regression analyses.

Results

XIST expression was increased in cholangiocarcinoma, while miR-126–3p was decreased, in both tissues and cells. The successful construction of silencing XIST was found to inhibit the count of cell migration and invasion. XIST directly targeted miR-126–3p to regulate the progression of cholangiocarcinoma.

Conclusion

XIST sponging miR-126–3p inhibited the progression of cholangiocarcinoma and improved the prognosis for patients. This finding provides new insights and opportunities for future studies on cholangiocarcinoma prognostic biomarkers.

Le texte complet de cet article est disponible en PDF.

Keywords : lncRNA XIST, miR-126–3p, Cholangiocarcinoma, Prognostic biomarker


Plan


© 2024  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 48 - N° 7

Article 102398- août 2024 Retour au numéro
Article précédent Article précédent
  • Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer
  • Nicolas Cazeneuve, Olivier Bouché, Julie Leger, Christophe Borg, Catherine Labbe-Devilliers, Olivier Lucidarme, Jean-Pierre Tasu, Sylvain Manfredi, Christophe Aubé, Hervé Trillaud, Philippe Manzoni, Claude Marcus, Eric Terrebonne, Jean-Yves Douillard, Romain Chautard, Sarah Lobet, Béatrice Scotto, Aurore Bleuzen, Thierry Lecomte
| Article suivant Article suivant
  • Validation of a novel BCM model for recurrence risk prediction after mucosectomy of colorectal lateral spreading tumors in a European cohort
  • Sofia Bragança, Ana Catarina Garcia, Gonçalo Alexandrino, Ana Maria Oliveira, David Horta, Luís Carvalho Lourenço, Mariana Nuno Costa

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.